Intrinsic Edge Capital Management LLC Buys 43,680 Shares of DexCom, Inc. (NASDAQ:DXCM)

Intrinsic Edge Capital Management LLC boosted its stake in DexCom, Inc. (NASDAQ:DXCM – Get Rating) by 300.0% in the second quarter, HoldingsChannel reports. The firm owned 58,240 shares of the medical device company’s stock after acquiring an additional 43,680 shares during the period. Intrinsic Edge Capital Management LLC’s holdings in DexCom were worth $4,341,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Los Angeles Capital Management LLC grew its stake in DexCom by 153.7% in the first quarter. Los Angeles Capital Management LLC now owns 2,083 shares of the medical device company’s stock valued at $1,066,000 after acquiring an additional 1,262 shares during the period. CWM LLC grew its stake in DexCom by 448.1% in the second quarter. CWM LLC now owns 2,801 shares of the medical device company’s stock valued at $209,000 after acquiring an additional 2,290 shares during the period. Truist Financial Corp grew its stake in DexCom by 295.9% in the second quarter. Truist Financial Corp now owns 112,220 shares of the medical device company’s stock valued at $8,364,000 after acquiring an additional 83,876 shares during the period. Prelude Capital Management LLC grew its stake in DexCom by 243.7% in the first quarter. Prelude Capital Management LLC now owns 5,293 shares of the medical device company’s stock valued at $2,708,000 after acquiring an additional 3,753 shares during the period. Finally, Jennison Associates LLC grew its stake in DexCom by 83.4% in the first quarter. Jennison Associates LLC now owns 2,600,283 shares of the medical device company’s stock valued at $1,330,305,000 after acquiring an additional 1,182,632 shares during the period. Institutional investors own 92.34% of the company’s stock.

DexCom Stock Up 1.3 %

DXCM traded up $1.56 on Thursday, hitting $117.84. 24,283 shares of the company were exchanged, compared to its average volume of 2,414,578. DexCom, Inc. has a 12 month low of $66.89 and a 12 month high of $149.51. The company has a market cap of $45.52 billion, a PE ratio of 214.34, a PEG ratio of 4.24 and a beta of 1.21. The company has a debt-to-equity ratio of 1.08, a quick ratio of 3.43 and a current ratio of 3.77. The stock’s fifty day moving average is $103.43 and its 200-day moving average is $88.85.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on DXCM shares. Cowen boosted their target price on DexCom from $85.00 to $114.00 in a research note on Friday, October 28th. StockNews.com started coverage on DexCom in a research report on Wednesday, October 12th. They set a “hold” rating for the company. Cowen upped their price objective on DexCom from $85.00 to $114.00 in a research report on Friday, October 28th. Robert W. Baird upped their price objective on DexCom from $97.00 to $120.00 in a research report on Friday, October 28th. Finally, Raymond James upped their price objective on DexCom from $101.00 to $125.00 and gave the stock an “outperform” rating in a research report on Friday, October 28th. Three analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $120.24.

Insider Buying and Selling at DexCom

In other DexCom news, CFO Jereme M. Sylvain sold 2,400 shares of the company’s stock in a transaction that occurred on Monday, November 21st. The stock was sold at an average price of $112.62, for a total value of $270,288.00. Following the sale, the chief financial officer now owns 67,237 shares in the company, valued at $7,572,230.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.41% of the company’s stock.

DexCom Profile

(Get Rating)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system.